Summary

Japan Human Insulin Market was valued at USD 840.23 Million in 2024 and is expected to reach USD 1206.28 Million by 2030 with a CAGR of 6.17% during the forecast period. The Japan Human Insulin Market is driven by several key factors. The rising prevalence of diabetes, particularly Type 2 diabetes among the aging population, significantly boosts demand for insulin therapies. Advances in insulin formulations, including rapid-acting and long-acting variants, enhance treatment options and patient compliance. The growing emphasis on personalized medicine and technological innovations, such as insulin pumps and continuous glucose monitoring systems, contribute to market expansion. Government initiatives and healthcare policies promoting better diabetes management also support market growth. Increased awareness and education about diabetes management drive the adoption of advanced insulin therapies, further propelling the market forward.
Key Market Drivers
Rising Prevalence of Diabetes
The increasing prevalence of diabetes in Japan is a primary driver of the Japan Human Insulin Market. Japan has been grappling with a significant diabetes burden, especially concerning Type 2 diabetes, which is closely associated with demographic changes and rising obesity rates. As Japan's population ages and the incidence of obesity grows, the number of diabetes cases continues to rise, creating a substantial healthcare challenge. Type 2 diabetes is particularly prevalent among the elderly, a demographic that is rapidly expanding in Japan. As people age, their risk of developing Type 2 diabetes increases due to a combination of declining insulin sensitivity and metabolic changes. Japan's lifestyle changes, including shifts in dietary habits towards more processed foods and reduced physical activity, have contributed to the rising obesity rates, which further exacerbate the risk of diabetes. The correlation between these factors and the increasing diabetes incidence highlights the growing demand for effective management solutions. According to an article, approximately 13.5% of the Japanese population is affected by either type 2 diabetes or impaired glucose tolerance. This high prevalence places a substantial economic burden on the healthcare system, with diabetes consuming up to 6% of the total healthcare expenditure. The financial impact is exacerbated for patients with additional co-morbidities, such as hypertension and hyperlipidemia, as well as those who develop complications, with diabetic retinopathy being the costliest. The economic burden increases as the number of complications rises. According to the Japan Diabetes Society (JDS) guidelines, a target HbA1c level of 6.5% is recommended for optimal glycemic control. This target is achieved in about one-third of patients with type 2 diabetes, who generally exhibit lower HbA1c levels compared to their counterparts in Western countries like the US and UK. Japanese patients typically show better adherence to diet and exercise recommendations than those in Western nations. While sulfonylureas have been the most commonly prescribed first-line treatment for type 2 diabetes, there is a growing trend toward combination therapies and insulin use.
The rising number of diabetes cases translates into an escalating need for effective insulin therapies. Insulin remains a cornerstone of diabetes management, especially for patients who do not achieve adequate glycemic control through oral medications alone. As the prevalence of diabetes increases, so does the demand for advanced insulin products capable of meeting diverse patient needs. For instance, some patients require long-acting insulins to maintain stable blood glucose levels over extended periods, while others may need rapid-acting insulins to manage postprandial glucose spikes effectively. This variation in treatment needs drives the demand for a wide range of insulin formulations. The complexity of managing diabetes necessitates the development of increasingly sophisticated insulin therapies. Pharmaceutical companies are responding to this demand by investing heavily in research and development to create new and improved Insulin. Innovations in insulin formulation, such as ultra-fast-acting insulins that mimic the natural insulin response more closely and ultra-long-acting insulins that offer extended glycemic control, are examples of how the industry is addressing the need for more tailored treatment options. These advancements aim to enhance patient outcomes by providing more effective and convenient ways to manage diabetes.
Aging Population and Increasing Life Expectancy
Japan’s aging population significantly drives the Japan Human Insulin Market, reflecting broader demographic and healthcare trends that impact diabetes management. As one of the countries with the highest life expectancies globally, Japan is experiencing a substantial increase in the number of elderly individuals. This demographic shift is crucial for understanding the rising demand for Insulin, as older adults are at a higher risk for developing Type 2 diabetes. Type 2 diabetes is particularly prevalent among older adults due to age-related physiological changes, such as decreased insulin sensitivity and pancreatic beta-cell dysfunction. As people age, their bodies become less efficient at regulating blood glucose levels, which can lead to the development or exacerbation of diabetes. This increased risk among the elderly highlights the pressing need for effective diabetes management solutions tailored to their specific needs. The aging population in Japan necessitates a shift towards diabetes management strategies that account for the unique challenges faced by older adults. Older patients often present with a distinct set of health issues compared to younger individuals, including multiple comorbidities such as hypertension, cardiovascular diseases, and renal impairments. These additional health conditions complicate diabetes management and require insulin therapies that not only control blood glucose levels but also accommodate these overlapping health concerns.
Specialized insulin formulations and treatment regimens are essential for this demographic. Older adults may require Insulin with specific characteristics, such as those that minimize the risk of hypoglycemia, which can be particularly dangerous for elderly patients. The pharmacokinetics and pharmacodynamics of insulin can change with age, necessitating formulations that are adapted to ensure efficacy while minimizing adverse effects. For instance, long-acting insulins may be preferred for their stability and convenience, reducing the frequency of injections and helping to maintain consistent glycemic control. The need for insulin therapies that are both effective and well-tolerated in older adults drives significant market demand. Pharmaceutical companies are increasingly focusing on developing insulin products that meet the needs of this aging population. Innovations in insulin delivery systems, such as pre-filled pens and smart insulin pumps, are designed to enhance patient compliance and ease of use. These advancements are crucial for older patients who may face challenges with manual injections or complex dosing regimens.
Increasing Awareness and Education on Diabetes Management
The growing awareness and education surrounding diabetes management play pivotal roles in driving the Japan Human Insulin Market. In recent years, significant efforts have been made through public health campaigns, educational programs, and support groups to enhance understanding and knowledge about diabetes. This heightened awareness has multiple implications for the Japan Human Insulin Market, leading to increased diagnosis rates, more informed treatment choices, and a greater emphasis on effective management solutions. Public health campaigns have been instrumental in spreading awareness about diabetes, its risk factors, and the importance of early diagnosis. These campaigns often utilize various media platforms, including television, social media, and community outreach events, to reach a broad audience. By highlighting the prevalence of diabetes and its potential complications, these campaigns encourage individuals to undergo regular screenings and seek medical advice if they exhibit symptoms. As a result, there is a higher rate of diabetes diagnoses, which directly influences the demand for insulin therapies.
Educational programs, both at the community level and within healthcare settings, further contribute to the growth of the Japan Human Insulin Market. These programs are designed to provide patients, caregivers, and healthcare professionals with up-to-date information about diabetes management. They cover a range of topics, from understanding diabetes and its types to learning about the latest advancements in insulin therapies and technologies. By equipping individuals with knowledge about how to manage diabetes effectively, these educational initiatives empower patients to make informed decisions about their treatment options. Support groups for individuals with diabetes also play a crucial role in raising awareness and improving diabetes management. These groups offer a platform for patients to share their experiences, exchange tips, and provide mutual support. They often host educational sessions with healthcare professionals who discuss various aspects of diabetes care, including the benefits of different insulin formulations and delivery methods. The information shared in these support groups helps patients better understand their condition and the available treatment options, leading to more proactive and informed choices regarding insulin therapy.
Expansion of Diabetes Care Infrastructure
The expansion of diabetes care infrastructure in Japan significantly contributes to the growth of the Japan Human Insulin Market by enhancing access to diabetes management and treatment services. This expansion encompasses the establishment and development of specialized diabetes clinics, comprehensive care centers, and dedicated diabetes management programs, all of which play a crucial role in improving patient care and driving demand for insulin therapies.
Specialized diabetes clinics represent a significant advancement in diabetes care infrastructure. These clinics are dedicated to the management of diabetes and are staffed by healthcare professionals with specialized expertise in the condition. They offer a comprehensive range of services, including diagnosis, treatment, and ongoing management of diabetes. By focusing exclusively on diabetes, these clinics are able to provide tailored care that addresses the specific needs of patients. They are equipped with advanced diagnostic tools, such as HbA1c monitors and continuous glucose meters, which enable precise monitoring of blood glucose levels. The availability of these specialized tools supports the effective management of diabetes and ensures that patients receive accurate and timely treatment. The increased presence of such clinics enhances the accessibility of diabetes care, leading to higher rates of insulin prescriptions and, consequently, growth in the Japan Human Insulin Market. Comprehensive care centers further contribute to the expansion of diabetes care infrastructure. These centers offer a multi-disciplinary approach to diabetes management, integrating various healthcare services under one roof. They typically include endocrinologists, dietitians, diabetes educators, and other specialists who collaborate to create individualized treatment plans for patients. The presence of such centers facilitates a holistic approach to diabetes care, addressing not only glycemic control but also related aspects such as diet, exercise, and lifestyle modifications. This comprehensive approach enhances patient management and adherence to treatment regimens, driving increased demand for Insulin as part of a broader care strategy.
Key Market Challenges
High Cost of Insulin
One of the primary challenges facing the Japan Human Insulin Market is the high cost associated with insulin therapies. Despite Japan's advanced healthcare system and substantial government subsidies for diabetes care, the financial burden of insulin products remains a significant issue. The cost challenge primarily stems from the expensive nature of innovative insulin formulations, which include ultra-fast-acting and ultra-long-acting insulins. These advanced therapies are often priced higher than traditional insulin options, making them less accessible to some patients. Ultra-fast-acting insulins, designed to more closely mimic natural insulin secretion and provide more precise control of blood glucose levels, come with a premium price. Similarly, ultra-long-acting insulins, which offer extended duration of action and can reduce the frequency of injections, also carry higher costs. These innovations, while providing substantial clinical benefits, are often priced beyond the reach of many patients, particularly those without comprehensive insurance coverage. The disparity in cost can lead to limited access to these advanced therapies, affecting the ability of patients to achieve optimal diabetes management.
For patients with inadequate insurance coverage or those facing significant out-of-pocket expenses, the high cost of innovative Insulin can be a major barrier to effective diabetes management. This financial strain may lead some patients to forgo or delay treatment, potentially resulting in poorly managed diabetes and increased risk of complications. The challenge is particularly acute for individuals on fixed or limited incomes, who may struggle to afford the latest insulin therapies despite their clinical advantages. While the introduction of biosimilar insulins aims to reduce the cost burden by providing more affordable alternatives to branded insulin products, these biosimilars can still be expensive. Biosimilar Insulin are developed to be highly similar to existing branded insulins, but their production involves complex biotechnological processes and stringent regulatory approvals. The complexity of manufacturing and the costs associated with meeting regulatory requirements contribute to the overall expense of biosimilars. Consequently, even though biosimilars are generally cheaper than their branded counterparts, they may still be costly for patients and healthcare systems.
Complexity of Diabetes Management
The complexity of diabetes management presents a significant challenge in the Japan Human Insulin Market. Diabetes treatment often involves a multifaceted approach that includes not only insulin therapy but also lifestyle modifications, regular monitoring, and management of comorbid conditions. The need for a comprehensive and personalized treatment plan can complicate the use of Insulin, as patients must navigate various insulin formulations, dosing schedules, and delivery methods. This complexity can lead to issues with adherence, as patients may struggle to follow complex regimens or understand the nuances of their treatment. Healthcare providers must stay abreast of the latest advancements and tailor treatments to individual patient needs, which adds to the challenge of effectively managing diabetes and ensuring optimal use of insulin therapies.
Key Market Trends
Rise in Innovative Insulin Formulations
The development of innovative insulin formulations is a major catalyst driving the growth of the Japan Human Insulin Market. Recent advancements in insulin technology have revolutionized diabetes management, introducing new insulin products that offer significant improvements over traditional therapies. These innovations include ultra-rapid and ultra-long-acting insulins, which provide enhanced glycemic control, reduced risk of hypoglycemia, and increased convenience for patients. Ultra-rapid-acting insulins represent a breakthrough in insulin therapy. Unlike conventional rapid-acting insulins, these formulations are designed to more closely mimic the natural insulin response to meals. They act faster, allowing for more precise control of postprandial blood glucose levels. This rapid action helps minimize post-meal blood sugar spikes, which can be challenging for diabetes patients to manage. The ability of ultra-rapid insulins to provide immediate glucose regulation enhances overall glycemic control and reduces the risk of hyperglycemia. The quicker onset and offset of these insulins also offer the potential for improved flexibility in meal timing and dosing, which contributes to better quality of life for patients. In June 2022, Taiwanese digital health startup Health2Sync and French multinational pharmaceutical company Sanofi entered into a new partnership to advance digital insulin management solutions in Japan. The collaboration will focus on developing digital features for insulin management, such as connected insulin caps and titration alerts. Health2Sync, which operates a mobile health app, already supports approximately 290,000 patients in Japan.
Similarly, ultra-long-acting insulins are designed to provide stable and extended blood glucose control over a prolonged period. These formulations offer a longer duration of action compared to traditional long-acting insulins, reducing the need for multiple daily injections. By providing a steady release of insulin, ultra-long-acting insulins help maintain more consistent blood glucose levels throughout the day and night. This steady insulin delivery minimizes fluctuations in blood glucose and lowers the risk of both hypoglycemia and hyperglycemia. The convenience of fewer injections and more predictable glucose control are significant advantages for patients, leading to improved adherence to treatment regimens and better overall diabetes management.
Technological Advancements in Insulin Delivery Systems
Technological advancements in insulin delivery systems are profoundly impacting the Japan Human Insulin Market. Innovations such as insulin pumps, continuous glucose monitors (CGMs), and smart insulin pens are revolutionizing diabetes management by offering enhanced precision, convenience, and patient engagement. These advanced delivery systems not only improve glycemic control but also drive demand for Insulin that are compatible with these technologies. Insulin pumps represent a significant leap in diabetes care, providing precise and continuous insulin delivery. Unlike traditional injection-based methods, insulin pumps deliver insulin in a steady, controlled manner throughout the day, mimicking the body’s natural insulin release. This continuous infusion allows for more stable blood glucose levels and reduces the frequency of hypoglycemic episodes. Patients using insulin pumps benefit from the ability to adjust insulin delivery rates based on their daily activities and dietary intake, leading to improved overall diabetes management. The integration of insulin pumps with advanced algorithms further enhances their efficacy, allowing for personalized adjustments to insulin delivery based on real-time glucose data. As the technology behind insulin pumps evolves, the demand for compatible insulin formulations that cater to these systems continues to grow.
Continuous glucose monitors (CGMs) are another technological advancement reshaping diabetes management. CGMs provide real-time monitoring of blood glucose levels, offering patients and healthcare providers a continuous stream of data on glucose trends. This real-time feedback enables proactive management of diabetes, allowing for timely adjustments to insulin therapy based on fluctuations in blood glucose levels. CGMs help reduce the risk of both hypoglycemic and hyperglycemic episodes by alerting patients to dangerous changes in glucose levels before they become critical. The ability to monitor glucose levels continuously and remotely supports more precise and informed insulin dosing, which can lead to better overall glycemic control. As CGM technology advances and becomes more widely available, the demand for Insulin that integrate seamlessly with these devices is expected to increase.
Segmental Insights
Product Type Insights
Based on the Product Type, rapid-acting insulin has emerged as the dominant category, driven by its significant advantages in managing blood glucose levels with precision and flexibility. Rapid-acting insulins, such as insulin lispro, insulin aspart, and insulin glulisine, are designed to mimic the natural insulin response to meals more closely than traditional insulin formulations. These insulins are characterized by their quick onset and short duration of action, typically beginning to work within 15 minutes of administration and peaking within 1-2 hours. This rapid action is particularly beneficial for patients needing tight control of postprandial blood glucose levels, helping to minimize spikes in blood sugar after meals and enhance overall glycemic control.
The growing prevalence of Type 2 diabetes in Japan, coupled with the increasing number of patients seeking more precise and flexible management options, has significantly contributed to the dominance of rapid-acting insulin in the market. As diabetes care continues to evolve, patients and healthcare providers are increasingly focusing on the ability to tailor insulin therapy to individual needs, which rapid-acting insulins facilitate by providing rapid glucose control and allowing for more predictable management of meals and snacks. The advancement of insulin delivery systems, such as insulin pumps and continuous glucose monitors (CGMs), has further driven the preference for rapid-acting insulins. These technologies work synergistically with rapid-acting formulations, offering continuous and precise insulin delivery based on real-time glucose data. The integration of rapid-acting insulins with advanced insulin delivery systems enhances the effectiveness of diabetes management, leading to improved patient outcomes and a growing demand for these products.
Application Insights
Based on Application, Type 2 Diabetes Mellitus (T2DM) is the dominant condition driving demand for insulin therapies. This dominance is attributed to several factors, including the high prevalence of T2DM in Japan, its association with aging and lifestyle changes, and the resulting demand for various insulin formulations tailored to manage this widespread condition effectively. Type 2 Diabetes Mellitus is characterized by insulin resistance and impaired insulin secretion, typically developing in adults and increasingly in younger populations due to rising obesity rates and sedentary lifestyles. In Japan, T2DM is a significant public health concern, with its prevalence steadily increasing due to an aging population and changing dietary habits. This trend is exacerbated by lifestyle factors such as high-calorie diets and low physical activity, which contribute to the development of insulin resistance. The high incidence of T2DM translates into a substantial demand for insulin therapies, as managing blood glucose levels becomes critical for preventing complications such as cardiovascular disease, neuropathy, and retinopathy.
The market for Insulin in Japan is therefore heavily influenced by the need to address the growing number of T2DM patients. The variety of insulin products available caters specifically to the needs of T2DM patients, offering options ranging from rapid-acting and long-acting insulins to combination therapies that provide both basal and bolus coverage. These products are designed to manage different aspects of diabetes, from mealtime glucose spikes to overall blood sugar control, reflecting the complexity and individualized nature of T2DM management.
Regional Insights
In the Japan Human Insulin Market, the Kanto region is the predominant force, driven by its extensive population base, economic strength, and advanced healthcare infrastructure. This region, encompassing Tokyo and Yokohama, boasts the largest population concentration in Japan, accounting for over 40% of the nation's inhabitants. The sheer volume of people contributes to a higher incidence of diabetes, particularly Type 2 Diabetes Mellitus, which in turn fuels significant demand for insulin therapies. Kanto's economic vitality further enhances its dominance in the market. As Japan's economic epicenter, the region enjoys robust healthcare funding and resources. This financial backing supports a wide array of healthcare facilities, from cutting-edge hospitals to specialized diabetes care centers. The concentration of such advanced infrastructure facilitates the adoption of new Insulin and technologies, ensuring that the latest therapies are readily available to patients.
The Kanto region is renowned for its sophisticated healthcare infrastructure. Tokyo and other major cities in the area host some of Japan’s most prominent medical institutions and research centers. These facilities are equipped with state-of-the-art technology and provide comprehensive diabetes care, including the latest insulin therapies. The presence of these high-caliber institutions drives the utilization of advanced insulin products and supports ongoing innovation in diabetes treatment. Public awareness and education about diabetes are also notably high in the Kanto region. Extensive diabetes education programs, health campaigns, and support groups contribute to better disease management and encourage the use of advanced insulin therapies. The region's proactive approach to public health education results in a higher rate of diabetes diagnosis and treatment adherence, further boosting the demand for Insulin. The Kanto region is a focal point for pharmaceutical and biotechnology research. Tokyo, in particular, serves as a hub for medical innovation, where new insulin formulations and delivery systems are developed and tested. This concentration of research activity accelerates the introduction of cutting-edge insulin therapies, driving market growth and enhancing the range of available treatment options.
Key Market Players
• Eli Lilly Japan K.K.
• Sanofi K.K.
• Novo Nordisk Pharma Ltd.
• Nippon Boehringer Ingelheim Co., Ltd.
• Novartis Pharma K.K.
• Janssen Pharmaceuticals K.K.
• Sun Pharma Japan Limited
• Otsuka Pharmaceutical Co., Ltd.
• Kyowa Pharma Chemical Co., Ltd.
• Santen Pharmaceutical Co., Ltd.
Report Scope:
In this report, the Japan Human Insulin Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:
• Japan Human Insulin Market, By Product Type:
o Rapid-Acting Insulin
o Long-Acting Insulin
o Combination Insulin
o Biosimilars
• Japan Human Insulin Market, By Application:
o Type 1 Diabetes Mellitus
o Type 2 Diabetes Mellitus
• Japan Human Insulin Market, By Type:
o Human Insulin
o Insulin Analog
• Japan Human Insulin Market, By Distribution Channel:
o Hospitals
o Retail Pharmacies
o Others
• Japan Human Insulin Market, By Region:
o Hokkaido
o Tohoku
o Kanto
o Chubu
o Kansai
o Chugoku
o Shikoku
o Kyushu
Competitive Landscape
Company Profiles: Detailed analysis of the major companies present in the Japan Human Insulin Market.
Available Customizations:
Japan Human Insulin Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:
Company Information
• Detailed analysis and profiling of additional market players (up to five).

ページTOPに戻る

Table of Contents

1. Product Overview
1.1. Market Definition
1.2. Scope of the Market
1.2.1. Markets Covered
1.2.2. Years Considered for Study
1.2.3. Key Market Segmentations
2. Research Methodology
2.1. Objective of the Study
2.2. Baseline Methodology
2.3. Key Industry Partners
2.4. Major Association and Secondary Sources
2.5. Forecasting Methodology
2.6. Data Triangulation & Validations
2.7. Assumptions and Limitations
3. Executive Summary
3.1. Overview of the Market
3.2. Overview of Key Market Segmentations
3.3. Overview of Key Market Players
3.4. Overview of Key Regions/Countries
3.5. Overview of Market Drivers, Challenges, Trends
4. Voice of Customer
5. Japan Human Insulin Drugs Market Outlook
5.1. Market Size & Forecast
5.1.1. By Value
5.2. Market Share & Forecast
5.2.1. By Product Type (Rapid-Acting Insulin, Long-Acting Insulin, Combination Insulin, Biosimilars)
5.2.2. By Application (Type 1 Diabetes Mellitus, Type 2 Diabetes Mellitus)
5.2.3. By Type (Human Insulin, Insulin Analog)
5.2.4. By Distribution Channel (Hospitals, Retail Pharmacies, and Others)
5.2.5. By Region
5.2.6. By Company (2024)
5.3. Market Map
6. Hokkaido Human Insulin Drugs Market Outlook
6.1. Market Size & Forecast
6.1.1. By Value
6.2. Market Share & Forecast
6.2.1. By Product Type
6.2.2. By Application
6.2.3. By Type
6.2.4. By Distribution Channel
7. Tohoku Human Insulin Drugs Market Outlook
7.1. Market Size & Forecast
7.1.1. By Value
7.2. Market Share & Forecast
7.2.1. By Product Type
7.2.2. By Application
7.2.3. By Type
7.2.4. By Distribution Channel
8. Kanto Human Insulin Drugs Market Outlook
8.1. Market Size & Forecast
8.1.1. By Value
8.2. Market Share & Forecast
8.2.1. By Product Type
8.2.2. By Application
8.2.3. By Type
8.2.4. By Distribution Channel
9. Chubu Human Insulin Drugs Market Outlook
9.1. Market Size & Forecast
9.1.1. By Value
9.2. Market Share & Forecast
9.2.1. By Product Type
9.2.2. By Application
9.2.3. By Type
9.2.4. By Distribution Channel
10. Kansai Human Insulin Drugs Market Outlook
10.1. Market Size & Forecast
10.1.1. By Value
10.2. Market Share & Forecast
10.2.1. By Product Type
10.2.2. By Application
10.2.3. By Type
10.2.4. By Distribution Channel
11. Chugoku Human Insulin Drugs Market Outlook
11.1. Market Size & Forecast
11.1.1. By Value
11.2. Market Share & Forecast
11.2.1. By Product Type
11.2.2. By Application
11.2.3. By Type
11.2.4. By Distribution Channel
12. Shikoku Human Insulin Drugs Market Outlook
12.1. Market Size & Forecast
12.1.1. By Value
12.2. Market Share & Forecast
12.2.1. By Product Type
12.2.2. By Application
12.2.3. By Type
12.2.4. By Distribution Channel
13. Kyushu Human Insulin Drugs Market Outlook
13.1. Market Size & Forecast
13.1.1. By Value
13.2. Market Share & Forecast
13.2.1. By Product Type
13.2.2. By Application
13.2.3. By Type
13.2.4. By Distribution Channel
14. Market Dynamics
14.1. Drivers
14.2. Challenges
15. Market Trends & Developments
15.1. Merger & Acquisition (If Any)
15.2. Product Launches (If Any)
15.3. Recent Developments
16. Japan Human Insulin Drugs Market: SWOT Analysis
17. Porter’s Five Forces Analysis
17.1. Competition in the Industry
17.2. Potential of New Entrants
17.3. Power of Suppliers
17.4. Power of Customers
17.5. Threat of Substitute Products
18. Competitive Landscape
18.1. Eli Lilly Japan K.K.
18.1.1. Business Overview
18.1.2. Company Snapshot
18.1.3. Products & Services
18.1.4. Financials (As Reported)
18.1.5. Recent Developments
18.1.6. Key Personnel Details
18.1.7. SWOT Analysis
18.2. Sanofi K.K.
18.3. Novo Nordisk Pharma Ltd.
18.4. Nippon Boehringer Ingelheim Co., Ltd.
18.5. Novartis Pharma K.K.
18.6. Janssen Pharmaceuticals K.K.
18.7. Sun Pharma Japan Limited
18.8. Otsuka Pharmaceutical Co., Ltd.
18.9. Kyowa Pharma Chemical Co., Ltd.
18.10. Santen Pharmaceutical Co., Ltd.
19. Strategic Recommendations
20. About Us & Disclaimer